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Abstract
The  central  nervous  system is  a  very  challenging  HIV-1  sanctuary.  But,
despite  complete  suppression  of  plasmatic  viral  replication  with  current
antiretroviral therapy, signs of  HIV-1 replication can still  be found in the
cerebrospinal  fluid  in  some  patients.  The  main  limitation  to  achieving
HIV-1 eradication from the brain is related to the suboptimal concentrations
of  antiretrovirals  within this  site,  due  to  their  low permeation across  the
blood–brain barrier. In recent years, a number of reliable nanotechnological
strategies  have  been  developed  with  the  aim  of  enhancing  antiretroviral
drug penetration across the blood–brain barrier. The aim of this review is to
provide an overview of the different nanoformulated antiretrovirals, used in
both  clinical  and  preclinical  studies,  that  are  designed  to  improve  their
delivery into the brain by active or passive permeation mechanisms through
the barrier. Different nanotechnological approaches have proven successful
for optimizing antiretrovirals delivery to the central nervous system, with a
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likely  benefit  for  HIV-associated  neurocognitive  disorders  and  a  more
debated contribution to the complete eradication of the HIV-1 infection.
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Introduction
Great progress has been made in antiretroviral therapy in the last decades,
with a significant improvement in clinical outcomes for HIV-1-infected
patients (Sarmati et al. 2012 ). However, complete eradication of HIV-1
remains an unmet need. The main concern is the persistent viral replication in
some physiological reservoirs, including anatomical (i.e. male genital tract,
lymph nodes, gut, bone marrow lymphoid structures and the central nervous
system) or cellular (i.e. latently infected CD4+ T cells, macrophages)
compartments. These sites, where HIV-1 is able to replicate despite treatment,
are poorly permeable to most antiretroviral drugs (ARVs), precluding a real
possibility of cure for patients (Svicher et al. 2014 ). Particularly, the central
nervous system (CNS) is a critical anatomical sanctuary for HIV-1. Indeed,
HIV-1 can quickly penetrate into the CNS after initial systemic infection
(Kramer-Hämmerle et al. 2005 ), promoting independent replication even if
the plasmatic viral load is suppressed (Canestri et al. 2010 ). HIV-1 invades
the CNS very early after infection: it has been retrieved in the cerebrospinal
fluid (CSF) as early as 8 days post-infection in one analysis (Valcour et al.
2012 ), although in a series of 42 acutely infected subjects 10, all in Fiebig
stages I – III, CSF HIV RNA was not measurable (Hellmuth et al. 20162015).
CSF escape, defined as HIV RNA above the lower limit of quantification
(LLQ) in CSF when ≤ LLQ in blood of patients on combination antiretroviral
therapy (cART) for more than 6 months, varies in prevalence between 4.4 and
13 % in various surveys (Edén et al. 2010 ; Rawson et al. 2012 ; Perez Valero
et al. 2012 ; Cusini et al. 2013 ; Pinnetti et al. 2014). In an observational
cohort after more than 3.5 years of ART, 60 % of 15 subjects maintaining
virological suppression in the plasma and CSF continued to have elevated
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=W0VTQU...
2 di 37 03/11/2016 15:43
CSF neopterin (Edén et al. 2007 ), a marker of dendritic cell activation and a
possible indirect sign of viral replication below the limits of assay detection.
Such data was confirmed in another study using an assay that could detect
down to 2.5 HIV RNA copies/mL, also showing a direct correlation between
CSF neopterin levels and measurable HIV-1 replication (Yilmaz et al. 2008 ;
Dahl et al. 2014 ). The functional magnetic resonance confirms the persistence
of brain inflammation in HIV infection on ART. After 12 weeks of stable
ART, 124 HIV-infected subjects had elevated myoinositol/creatinine in all
brain regions and choline/creatinine in the basal ganglia and mid-frontal
cortices, despite HIV RNA being undetectable in plasma in 79 % of subjects
and in CSF of 62 % of subjects (Harezlak et al. 2011 ). In a study of 252
HIV-infected subjects, CSF neurofilament light chain (indicator of neuronal
breakdown) decreased after ART initiation in 63 % of subjects (P < 0.01), but
remained still higher in virally suppressed subjects compared to HIV-negative
controls (Jessen Krut et al. 2014 ). Similarly, the in vivo analysis of
cell-associated HIV DNA during acute vs chronic infection, and the
post-mortem analysis of brain tissue from subjects deceased for causes other
than HIV while virologically suppressed, also demonstrated
compartmentalization in the majority of patients, and showed that it occurs
very early after estimated infection (De Oliveira et al. 2016 ; Lamers et al.
2016 ).
AQ1
AQ2
HIV-1 infection of the CNS leads to a broad spectrum of neurological
syndromes, which includes dementia, mild neurocognitive disorder and
asymptomatic impairment (McArthur et al. 2003 ; Grant et al. 2014 ; Watkins
and Treisman 2015), establishing so called “neuroAIDS” (Sagar et al. 2014 ).
A sub-analysis of the CHARTER cohort (Cysique and Brew 2011) showed
that after 5 years of optimal viral suppression on ART, 18.1 % of 116 subjects
presented neuropsychological impairment, and such percentage grows to
62.8 % in an Italian study (Tozzi et al. 2007 ) when subjects with baseline
HIV-associated cognitive impairment were selected.
AQ3
Altogether, these studies suggest that direct and indirect markers of CNS
inflammation and damage are reduced, but not eliminated by ART, even with
plasma suppression below the thresholds of detection, suggesting persistent
HIV integration or in some cases ongoing low level replication within the
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CNS, thus suggesting a CNS reservoir for infection. The employment of
single-genome amplification or deep sequencing has allowed better insight in
the phenomenon of compartmentalization, which is the generation of locally
replicating HIV subpopulations, that diverge from the circulating virus and are
more resistant to therapy. Several contributions at the “Conference on
Retroviruses and Opportunistic Infections (CROI) 2016” have focused on this
phenomenon, correlating it with the presence of HIV Associated
Neurocognitive Disorders (HAND) before therapy (Stefic et al. 2016), poorer
neurocognitive response to cART (Bowman et al. 2016 ), development of drug
resistance patterns at virologic failure that differ from those detected in the
blood (Evering et al. 2016 ), and transient viral escape with T-cell tropic virus
or persistent viral escape with macrophage-tropic virus (Joseph et al. 2016 ).
T-cells may be critical sources of CNS HIV in early infection (Sturdevant et
al. 2015 ), however perivascular macrophages and microglia are considered to
be the cells that mainly harbour HIV replication in chronic HIV infection
(Schnell et al. 2011 ; Joseph et al. 2015 ). Both cell populations are long-lived,
and microglia are thought not to undergo renewal from peripheral sources
during an individual’s life-span (Perry and Teeling 2013 ; Ginhoux et al.
2010 ). HIV-1 causes extensive infection of actrocytes that play an important
role in the development of HIV-1 associated neurocognitive disorders.
Astrocytes lack surface CD4 expression, but can internalize the virus through
CD81 vesicles and thus transfect other cells, without viral replication
occurring in them (Gray et al. 2014). A recent study has found that anti
CXCR4 but not anti CD4 antibodies inhibit the infection of astrocytes,
suggesting another mechanism for the entry of viral particles in these cells (Li
et al. 2016). In brain samples from patients died with HAND, 20 % of
astrocytes were infected, a proportion comparable to that of CD4+
T-lymphocytesT lymphocytes in the lymphoid tissue (Churchill et al. 2009 ),
however these cells may be unable to propagate the infection (Gorry et al.
2003 ). A high concentration of infected monocytes and microglial cells
supports the inflammatory escalation leading to astrogliosis and
neurodegeneration in the brain, and the mechanism by which HIV-1 infected
cells affect the CNS has been described in detail by S Kramer-Hämmerle et al.
( 2005). The mechanism involves the release of several factors of viral or
cellular origin from infected glial cells, which are able to damage the CNS
either by a direct interaction with neurons, or by indirectly stimulating
non-infected cells to produce inflammatory and neurotoxic molecules, such as
chemoattractant proteins, which call back infected or activated monocytes and
lymphocytes (Fig. 1 ).
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Fig. 1
Mechanism of  HIV-1 related damage to  the central  nervous system. Viral  or
cellular factors, released by infected and/or activated glial cells, injury the CNS
either by a direct  interaction with neurons or by activating the production of
molecules by other uninfected cells. These factors are neurotoxic substances or
chemotactic molecules, able to promote the infiltration of infiltration of infected
or activated monocytes and lymphocytes into the brain. Reprinted from Virus
Research (Vol.  111,  Issue 2),  Kramer-Hämmerle S,  Rothenaigner  I,  Wolff  H,
Bell JE, Brack-Werner  R “Cells of  the central  nervous system as targets and
reservoirs of  the human immunodeficiency virus”,  pages  194–213, Copyright
(2005), with permission from Elsevier
AQ4
AQ5
Thus, the CNS reservoir seems to be composed of multiple cell types within
the brain parencvhima, meninges, CSF and choroids plexus (Petito et al.
1996 ), with variations during the natural history of the disease (i.e.: acute vs
chronic vs neurologically symptomatic infection). HIV-associated
neurocognitive disorders and opportunistic diseases of the CNS (i.e.
multifocal leukoencephalopathy and tuberculous or cryptococcal meningitis)
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have been associated with unsatisfactory viral control (Tozzi et al. 2005 ) and
heavily impact on patients’ outcomes and quality of life (Hong and Banks
2015 ), underlying the clinical relevance of achieving an adequate control and
prophylaxis of HIV-1 infection of the brain.
In this context, the low penetration of ARVs into the CNS represents a major
concern. The blood–brain barrier (BBB), composed of a layer of brain
microvascular endothelial cells (BMECs) supported by pericytes and
astrocytes, constitutes a selective interface between the blood stream and the
brain parenchyma (Zhang et al. 2015 ). The impermeability of the BBB to
these drugs, and to most hydrosoluble drugs with a molecular weight >400 Da
(Banks 2009), is due to: 1) the extreme tightness of endothelial junctions
(50–100-fold higher than the peripheral vessels) and 2) the endothelial
expression of P-glycoprotein (P-gp), a drug efflux transporter which pumps
drugs out of the cell, hampering their intracellular accumulation, in an attempt
to protect the brain from xenobiotic exposure (Schinkel 1999 ). The direct
involvement of the P-gp in the limited accumulation of ARVs into the CNS
has been investigated only with protease inhibitors (PIs). A first study
performed on the mdr1a−/− mouse model clearly demonstrated the role of
P-gp in limiting the brain concentrations of the PIs indinavir (IDV), nelfinavir
(NFV) and saquinavir (SQV) (Kim et al. 1998). More recently, the
involvement of P-gp in reducing ARVs’ permeation into mouse brains has
been also demonstrated with atazanavir (ATV) (Robillard et al. 2014 ).
Recently, nanotechnology has been demonstrated to be a promising strategy
for improving the availability of ARVs to the CNS, and several nanostructured
delivery systems have been developed to properly direct these drugs into the
sanctuary site, escaping the physiological mechanisms of the BBB. The aim of
this review is to provide an overview of current nanotechnological approaches
to deliver ARVs into the CNS.
Steps towards HIV-1 eradication
HIV-1 latency in cells is mainly, but perhaps not only, established in infected
resting memory CD4+T cellsCD4+ T cells, which account for 1 in 10  resting
CD4+T-cellsCD4+ T cells (Fletcher et al. 2014), and multiple mechanisms
seem to cooperate to establish and maintain latency. Among them perhaps the
most important role is played by interference on gene expression at the site of
integration and the effect of repressive chromatin (Shan et al. 2011 ; Hakre et
al. 2011). Research in the field of eradication is currently focusing on small
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molecules called latency reversing agents, that probably need to act in
association with cART, selectively reactivating HIV proliferation in latently
infected cells. They include histone deacetylase inhibitors (Rasmussen et al.
2013 ), histone methyltrasnferase inhibitors (Bouchat et al. 2012 ), protein-
kinase C agonists (Darcis et al. 2015 ; Spivak et al. 2015 ), proteasome
inhibitors (Miller et al. 2013) and toll-like receptor 7 agonists (Whitney et al.
2015 ).
AQ6
An ongoing study by the SEARCH (South East Asia Research Collaboration
with Hawaii) group is currently recruiting participants to assess the effect of
adjunctive telmisartan employment with ART during acute HIV infection to
reduce the CNS reservoirs of HIV and lymph node fibrosis (
https://clinicaltrials.gov/ct2/show/NCT02750059 ), which will be evaluated in
terms of CSF neopterin concentration, functional magnetic resonance
spectroscopy (fMRS) imaging and inguinal lymph node biopsies.
AQ7
Blood–brain barrier selectivity to ARVs
The BBB has been demonstrated to be rather impermeable to most
antiretroviral drugs (Sagar et al. 2014 ), even if some of them can penetrate
into the CNS a certain amount. An exhaustive summary of all the studies
performed up to 2011 on this topic has been provided by Ene and colleagues
(Ene et al. 2011). Except for nevirapine (NVP), which is the only ARV able
to efficiently cross the BBB with a high CSF/plasma concentration ratio
(about 0.5), all the other ARVs display negligible or low CSF concentration.
Among them, the nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) zidovudine (ZDV), lamivudine (3TC), stavudine (D4T), didanosine
(DDI) and abacavir (ABC) can partially cross the BBB (>0.06 CSF/plasma
concentration ratio), possibly due to their low molecular weight and protein
binding rates. IDV shows a penetration rate into the CSF comparable to
NRTIs, with a mean CSF/plasma concentration ratio equal to 0.17 (Solas et al.
2003 ). Conversely, the endothelial barrier is poorly permeable to some
protease inhibitors (amprenavir (APV) and darunavir (DRV), 0.01–0.06 of
CSF/plasma concentration ratio) and almost impermeable to others such as
ritonavir (RTV), lopinavir (LPV), NFV, SQV, and ATV. The CSF
concentration of non-nucleosidic reverse-transcriptase inhibitors (NNRTIs)
such as efavirenz (EFV) is also very low (0.004–0.005 of CSF/plasma ratio)
(Yilmaz et al. 2012 ), although it exceeds its IC50 value in wild-type HIV and
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is therefore sufficient to exert a therapeutic activity in the brain (Best et al.
2011 ). The inhibitor of CCR5 co-receptors maraviroc (MVC) (Yilmaz et al.
2009 ), the integrase strand transfer inhibitor (INSTI) raltegravir (RGV)
(Letendre et al. 2009 ) and the NRTI tenofovir (TDF) (Best et al. 2012 ) are all
able to reach the CSF in low but detectable amounts (0.038,0.056 and 0.057
CSF/plasma concentration ratio, respectively). Finally, BBB penetration by
the fusion inhibitor enfuvirtide (ENF) is totally negligible (Price et al. 2008 ).
Figure 2  summarizes the rank order of ARVs penetration across the BBB.
Fig. 2
Permeability  rank  order  of  ARVs  across  the  BBB.  The  rate  of  permeation,
calculated as CSF/plasma concentration and graphically represented by arrows
width, is: nevirapine (NVP) > zidovudine (ZDV), lamivudine (3TC), stavudine
(D4T),  didanosine  (DDI),  abacavir  (ABC),  indinavir  (IDV)  >  amprenavir
(APV),  darunavir  (DRV),  maraviroc  (MVC),  raltegravir  (RGV),  tenofovir
(TDF) > ritonavir (RTV), lopinavir (LPV), nelfinavir (NFV), saquinavir (SQV),
atazanavir (ATV), efavirenz (EFV). Enfuvirtide (ENF) concentration in CSF is
undetectable. BMEC: brain microvascular endothelial cell
Nanoparticles for drug delivery
The main pharmacological factors influencing drug delivery to the brain are
lipophilicity, molecular weight and charge, chemical structure and
conformation, systemic absorption, affinity for receptors, efflux proteins and
carriers, clearance rate, dissolution rate and particle size flexibility and
permeability. Approaches to increase drug permeability have been
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lipidization, research on prodrugs, enzymatic physicochemical, site-specific
enzyme-activated and receptor-based chemical drug-delivery systems, and
molecular packaging, but all these strategies have limitations (Lu et al. 2014 ).
In the last fifteen years, nanotechnology has provided a generation of organic
and inorganic nanoparticles (NPs) with the aim of optimizing diagnostic and
therapeutic applications in various biomedical fields. Regarding drug delivery,
nanoformulation can offer some key advantages, such as an improved blood
half-life and bioavailability, a higher aqueous stability, and a precise delivery
due to functionalization with targeting moieties, reducing the administered
dose and the dose-related side effects. The peculiar physicochemical features
of inorganic nanoparticles (i.e. iron oxide, gold or manganese NPs), make
them the best candidates for photothermal or radiation therapy (Cooper et al.
2014 ; Cherukula et al. 2016 ) as well as tumor hypertermia (Kobayashi
2011 ), and imaging for cancer (Corot and Warlin 2013 ), inflammatory (Wu et
al. 2016 ) and infectious diseases (Chi et al. 2012 ). Moreover, the
characteristic properties of these NPs allow them a contemporary diagnostic
and therapeutic application, resulting in them being powerful theranostic tools
(Corsi et al. 2011 ; Gobbo et al. 2015). Although different types of inorganic
NPs have been investigated as drug delivery systems (Paciotti et al. 2004 ;
Wang et al. 2015 ), to date organic NPs have shown the most exciting
applications in therapeutics delivery. Some nano-products, mainly devoted to
cancer management, are now FDA-approved or under various stages of
clinical study, and the liposomal and polymeric NPs are the most represented
(Mitragotri and Stayton 2014 ).
For brain delivery, different classes of NPs have been identified as valid tools
for driving drugs to the CNS. Some examples are reported in Table 1 . A
major role is played by lipidic NPs (liposomes and solid lipid nanoparticles).
The chemical-physical features of lipidic NPs allow them to easily cross the
BBB (Kaur et al. 2008 ; Lai et al. 2013 ), and their capability of reaching the
CNS is further increased by surface engineering with BBB targeting moieties
(Re et al. 2011 ; Singh et al. 2016 ) or cell-penetrating peptides (CPPs) (Qin et
al. 2012 ). Lipidic NPs have the advantage of being non-toxic and
biodegradable, since they are made of naturally occurring compounds.
Moreover, liposomal encapsulation of drugs avoids their degradation and
reduces the possible systemic toxicity of loaded drugs. On the other hand,
their use is limited by their low storage stability and encapsulation efficiency,
together with a rapid leakage of hydrosoluble molecules. Polymeric NPs,
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properly modified to obtain an effective passive or active trans-BBB
permeability, were also profoundly investigated for drug delivery to the CNS
(Kreuter 2014 ; Saucier-Sawyer et al. 2015 ; Vilella et al. 2015). Among
them, surfactant-coated nanoparticles, which represent the most investigated
models (Steiniger et al. 2004 ; Petri et al. 2007 ; Wilson et al. 2008 ; Sun et al.
2015 ), are able to drive drugs across the BBB by exploiting the adsorption of
low density lipoproteins (LDL) from blood plasma onto the nanoparticle
surface and the interaction with the LDL receptors on the plasma membrane
of the endothelial cells. Polymeric NPs, as lipidic NPs, are characterized by a
high biocompatibility, biodegradability and loading capability. In addition,
these nanoparticles are water-soluble, show an efficient controlled release
profile, and their synthesis is simple and inexpensive. Several studies have
been aimed at improving the trans-BBB permeation of magnetic NPs,
exploiting encapsulation in polymeric or liposomal shells, or the application
of an external magnetic field, or surface modification with ligands directed
against receptors expressed on the apical membrane of endothelial cells (Qiao
et al. 2012 ; Thomsen et al. 2015 ; Busquets et al. 2015 ). Other inorganic NPs
were designed to pass through the BBB, exploiting enhanced endothelial
permeability allowed by surface functionalization. Small sized silica NPs have
been demonstrated to cross the BBB in vitro and in vivo upon surface
modification with polyethylene glycol (PEG) (Liu et al. 2014 ). Gold
nanoparticles are able to cross the barrier when conjugated to CPPs, resulting
in improved delivery of anticancer drugs and contrast agents to brain gliomas
(Cheng et al. 2014 ). Finally, some studies demonstrated the employment of
functionalized quantum dots for crossing the BBB; these were mainly focused
on the delivery of HIV-targeted drugs (Xu et al. 2013 ), as reported below.
Despite the advantage of inorganic NPs being able to combine drug delivery
functions with multimodal imaging capabilities, a limitation in their
biomedical employment is related to toxicity concerns about these
nanomaterials. Much data is currently available about this topic, but much
more effort is still required to completely elucidate this issue, starting with the
different physicochemical and physiological factors behind the interaction of
NPs with biological systems (Choi et al. 2013). Recent advances have been
directed at reducing toxicity of inorganic NPs, mainly by controlling particle
size and surface coating and therefore, optimizing their biodegradation and
pharmacokinetic features (Ehlerding et al. 2016 ).
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Table 1
Overview of nanoparticles for the drug delivery across BBB
Nanoparticle Drug Experimental Nano-compound
Lipidicnanoparticles
Derivative of5-Fluorouracil(FU) In vivo model
DO-FUdR-solid lipidNPs (Wang et al. 2002 )
Doxorubicin In vivo model stearic acid-PEG2000-solid lipid NPs(Zara et al. 2002 )
Nitrendipine In vivo model
Solid lipid NPs(Manjunath andVenkateshwarlu 2006 )AQ8
Daunorubicin Glioma cells, invitro BBB modeland in vivo model
MAN-liposomes-Tf(Ying et al. 2010 )
Doxorubicin Glioma cells andin vivo model
Lf-procationicliposomes (Chen et al.2011 )
Curcuminderivative In vitro BBBmodel ApoE-liposomes (Re etal. 2011 )
– Brain capillaryendothelial andglioma cells
TAT/D-TAT/R8-liposomes (Qin et al.2012 )
Docetaxel Glioblastoma cellsand in vivo model Lf-solid lipid NPs(Singh et al. 2016 )
Polymericnanoparticles
Doxorubicin In vivo models
PS80/P188-coatedPBCA NPs (Steiniger etal. 2004 ; Petri et al.2007 )
Loperamide In vivo model g7-PLGA NPs (Tosi etal. 2007 )
Abbreviations: NPs nanoparticles, MNPs magnetic nanoparticles, PLA poly(lacticacid), PEG poly ethylenglycol, PLGA poly(lactide-co-glycolide), PBCA poly(butylcyanoacrylate), p(HPMA)-co-p(LMA) p(2-hydroxypropyl-methacrylamide)-co-p(laurylmethacrylate) amphiphilic copolymer, BCNU 3-bis(2-chloroethyl)-1-nitrosourea, DO-FUdR 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine, Ad adenosine,Ap DNA aptamer, ApoE apolipoprotein E, HPG hyperbranched polyglycerol, PS80polysorbate 80, P188 poloxamer 188, Tf transferrin, Lf lactoferrin, MANp-aminophenyl-α-D-mannopyranoside, TAT Cys-AYGRKKRRQRRR, D-TATCys-RKARYRGRKRQR, R8 Cys-RRRRRRR, g7 H N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-CONH
In the presence of an external magnetic force
2
2
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Nanoparticle Drug Experimental Nano-compound
Abbreviations: NPs nanoparticles, MNPs magnetic nanoparticles, PLA poly(lacticacid), PEG poly ethylenglycol, PLGA poly(lactide-co-glycolide), PBCA poly(butylcyanoacrylate), p(HPMA)-co-p(LMA) p(2-hydroxypropyl-methacrylamide)-co-p(laurylmethacrylate) amphiphilic copolymer, BCNU 3-bis(2-chloroethyl)-1-nitrosourea, DO-FUdR 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine, Ad adenosine,Ap DNA aptamer, ApoE apolipoprotein E, HPG hyperbranched polyglycerol, PS80polysorbate 80, P188 poloxamer 188, Tf transferrin, Lf lactoferrin, MANp-aminophenyl-α-D-mannopyranoside, TAT Cys-AYGRKKRRQRRR, D-TATCys-RKARYRGRKRQR, R8 Cys-RRRRRRR, g7 H N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-CONH
In the presence of an external magnetic force
Rivastigmine In vivo model PS80-coated PBCA NPs(Wilson et al. 2008 )
Paclitaxel Glioma cells andin vivo model Ap-PEG-PLGA NPs(Guo et al. 2011 )
Domperidone In vivo model p(HPMA)-co-p(LMA)NPs (Hemmelman et al.2011 )
BCNU In vivo model Tf-PLA (Han et al.2012 )
Acetylpuerarin In vivo model PS80-coated PLGA NPs(Sun et al. 2015 )
Camptothecin
Brain capillaryendothelial andglioblastoma cells,and in vivo model
PLA-HPG-Ad NPs(Saucier-Sawyer et al.2015 )
Inorganicnanoparticles
Paclitaxel Glioma cells andin vivo model MNPs (Zhao et al.2010 )
– In vitro BBBmodel and in vivomodel
Lf-PEG-coated Fe ONPs (Qiao et al. 2012 )
Doxorubicin Glioma cells andin vivo model TAT-gold NPs (Cheng etal. 2014 )
– In vitro BBBmodel and in vivomodel
PEG-Silica NPs (Liu etal. 2014 )
– In vitro BBBmodel
Tf-MNPs-loadedliposomes (Ding et al.2014 )
Candidate ARVs for nanoformulation
2
2
a
a
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a
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Provided that HIV-infected subjects harboring drug-resistant viral strains do
not have standardized needs for therapy, but rather their choice is constrained
by resistance, and therefore it is desirable that the widest number of
antiretrovirals be nanoformulated to reach the CNS, there are some drugs and
drug classes that are particularly promising and others that show neurologic
tolerability problems. NRTIs are a widely differentiated class, in which 3TC,
emtricitabine (FTC), ABC and TDF are not associated to neurologic adverse
events. Moreover, such drugs have proven to be the most effective backbone
on sensitive HIV-1 strains and very active on brain macrophages (Senanayake
et al. 2015). Protease inhibitors, the class that revolutioned the antiretroviral
therapy, today appear weaker in comparison to some NNRTIs (Bonora et al.
2009 ) and to INSTIs (Molina et al. 2015 ). Moreover, PIs more than other
compounds are associated to the formation of 2’LTR circles and to the
reduction of inflammation upon intensification with RGV, an indirect sign of
persistent viral replication (Buzón et al. 2010 ; Massanella et al. 2014 ). On
the other side, among NNRTIs, EFV and to a lower extent rilpivirine show
some degree of neurologic and psychiatric side effects (Mills et al. 2013 ).
Among INSTIs, RGV can cause headache, reported between 2.2 and 16.1 %
of recipients in phase 2–3 studies (Temesgen and Siraj 2008 ) and also
dolutegravir (DTG) is associated to headache and insomnia in clinicals
(Kandel and Walmsley 2015 ). However, a RGV-based intensification strategy
is in progresshas been recently completed to reduce the persistent
immunoactivation within the CNS, which may hypothetically lead to
long-term brain damage in the presence of minimal viral replication, and
results are awaited soon ( https://clinicaltrials.gov/ct2/show/NCT00672932 ).
Another ongoing study is evaluating the effect of switching stably suppressive
EFV to RGV, in combination with a TDF/FTC backbone, on CNS biological
changes, detected through neuroimaging ( https://clinicaltrials.gov/ct2/show
/NCT01978743 ). Investigators are using fMRS to measure changes in brain
neurometabolites associated to long-term EFV and to the switch to RGV,
looking for a correlation with modifications in cognition assessed by Trail
Making and Digit Substitution Tests, and with changes in emotion and sleep
quality. In the near future, a further study is expected to compare CNS effects
in the switch from EFV to DTG, based on clinical evidences and not on the
use of questionnaires ( https://clinicaltrials.gov/ct2/show/NCT02285374 ).
Among the biologic drugs, i.e. drugs that may be able to modulate the immune
response in the brain, only dimethyl fumarate has been hypothesized as a
possible option, but to date no clinical studies have been planned (Gill and
Kolson 2013 ).
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ARVs nanoformulation to overcome theblood–brain barrier
To prevent neuroAIDS nanotechnology has been intensely explored, with the
aim of developing novel and promising drug delivery systems in order to
improve the ability of ARVs to reach the CNS at suitable amounts to allow
them to suppress viral replication in this sanctuary site. Several experimental
attempts have been carried out in recent years in order to increase the BBB
permeability for antiretroviral drugs (Fig. 3 ).
Fig. 3
Different types of nanoformulations employed to deliver ARVs across the BBB.
Non-specific  delivery  strategies  have  been  employed,  based  on  liposomes,
CPPs, PLGA NPs, PMA-coating metallic NPs and nanoART, for the delivery of
ritonavir  (RTV),  saquinavir  (SQV),  atazanavir  (ATV),  lamivudine  (3TC),
tenofovir  (TDF),  foscarnet  (PFA),  enfuvirtide  (ENF),  azidothymidine  (AZT),
lopinavir (LPV), efavirenz (EFV) and azidothymidine 5-triphosphate (AZTTP).
A  macrophage-mediated  permeation  of  the  BBB  has  been  studied  with
nanoART loaded with ATV, RTV and indinavir (IDV). Actively targeted NPs
has  been  developed  for  the  delivery  of  SQV,  AZT,  stavudine  (D4T),  and
delavirdine (DLV). BMEC: brain microvascular endothelial cell
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Liposomes
As introduced above, a great effort has been made to design an effective NP
for drug delivery to the brain, with lipidic NPs and, in particular, with
liposomes. A liposome-based nanoformulation of foscarnet (PFA), an antiviral
drug mainly used for treatment of cytomegalovirus (CMV) infections but also
employed in combination with other ARVs in HIV-1 selvage therapy (Canestri
et al. 2006 ; Delory et al. 2015 ), was demonstrated to increase by 13 times its
brain accumulation in rats compared to the soluble free drug (Dusserre et al.
1995 ). However, liposomes are characterized by a short half-life because they
tend to be sequestered by the reticuloendothelial system, and their
encapsulation is particularly inefficient with water-soluble drugs (Torchilin
2005 ). A more appealing application of these NPs has been investigated with
magnetic liposomes composed of phosphatidyl choline-cholesterol and
magnetite, and encapsulated with azidothymidine 5-triphosphate (AZTTP),
the active form of zidovudine, also named azidothymidine (AZT) (Saiyed et
al. 2010 ). Interestingly, these nanocompounds demonstrated a 3-fold higher
permeability through the BBB compared to free drugs, due both to direct
transmigration and to monocyte-mediated transport; in both cases, the
presence of an external magnetic field guided the permeation of the BBB
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(Saiyed et al. 2010 ).
NanoART
In 2009In 2009, Nowacek and Gendelman 2009  described how ARVs
nanoformulated with different surfactants and by different methodological
approaches (“nanoART”) could be engaged to improve drug permeability into
the brain. A study from Kuo and Chen ( 2006 ) demonstrated how
incorporation of AZT and 3TC into polybutylcyanoacrylate (PBCA) and
methylmethacrylate-sulfopropylmethacrylate (MMA-SPM) nanoparticles
increased their permeability across the BBB, through absorptive endocytosis
by endothelial cells. In subsequent research, the same authors developed a
cationic solid lipid nanoparticle (CSLN) for SQV encapsulation, stabilized
with polysorbate 80 and composed of nonionic Compritol 888 ATO and cacao
butter in a lipid core center, and cationic stearylamine and
dioctadecyldimethyl ammonium bromide in the core periphery. This nanoART
showed a high entrapment efficiency and optimal release kinetics of SQV,
being a valid tool for transport of ARVs across the BBB (Kuo and Chen
2009 ). The nanoformulation of IDV in a Lipoid E80-based nanoART allows
prompt absorption and release by human monocyte-derived macrophages
(MDM), with a sustained anti-retroviral activity in these cells (Dou et al.
2007 ). This strategy has been exploited to deliver IDV-NP, loaded into bone
marrow macrophages (BMM), across the BBB. After injection of
IDV-NP-BMM in mouse models of HIV-1 encephalitis, the IDV was readily
detected in the brain and specifically in encephalitic subregions, where a
significant antiretroviral activity was also observed (Dou et al. 2009).
AQ14
More recently, ATV and RTV crystalline nanoART formulated with
poloxamer-188 by high-pressure homogenization, have been demonstrated to
exert a protective role in the infected brain sub-regions of mice (Dash et al.
2012 ). Moreover, ATV-, RTV-, IDV- and EFV-based nanoART exploit
monocyte-derived macrophages as “Trojan horses” to enter brain BMECs.
This strategy, involving a cell-to-cell contact between macrophages and brain
endothelium, resulted in a highly efficient passage of ATV and RTV across
the BBB in vivo, with a penetration into the CNS up to 4-fold higher with
folate-coating of nanoART (Kanmogne et al. 2012 ). In a recent study,
magnetic nanoART has been developed by assembling anti-HIV drugs around
an ultrasmall iron oxide NP, using a magnetically guided layer-by-layer (LbL)
technique. The LbL technique allowed co-loading of TDF and vorinostat
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(latency-breaking agent). This nanodrug has shown a sustained drug release of
up to 5 days, with an acceptable BBB transmigration (about 38 %) and a
decrease of p24 levels in 33 % of infected human astrocytes (Jayant et al.
2015 ).
TAT-NPs
The use of CPPs as carriers of therapeutic agents across the BBB is also
promising. Indeed, this class of peptides, which can be internalized by cells
through mechanisms still not completely clarified, presents some evident
advantages; such as a simple synthesis, a high internalization rate and a low
cytotoxicity. Nevertheless, in vivo application of CPP is limited by its lack of
specificity in targeting cells and its accumulation in off-target cells (Jafari et
al. 2015 ). Among CPPs, the cationic trans-activating transcriptor (TAT)
peptide is one of the most used to enhance trans-BBB permeation capability.
In 2008, Rao et al. showed that TAT-Poly-L-lactide (PLA) nanoparticles
loaded with RTV significantly improved the trans-BBB delivery of the drug in
mouse models. This strategy allowed it to escape the P-glycoprotein efflux
action, with a 800-fold higher RTV level in the brain after 2 weeks of
treatment. Moreover, the BBB integrity was not disrupted and therefore, a
transcytotic mechanism typical of TAT-conjugated cargoes has been suggested
to explain RTV permeation across brain endothelium.
Actively targeted NPs
Another research trend has highlighted the importance of active targeting for
an effective drug delivery into the CNS. Exploiting the over-expression of the
transferrin receptor-1 (TfR-1) on the apical side of the BBB endothelium
(Jefferies et al. 1984 ), some studies reported the conjugation of transferrin
(Tf) to quantum rods to obtain a smart delivery system of drugs into the CNS
through TfR-1 binding (Xu et al. 2008 ). This strategy enhanced the
trans-BBB permeation of SQV in vitro, increasing its antiviral activity on
infected peripheral blood mononuclear cells cultured at the basolateral end of
the BBB model (Mahajan et al. 2010). Transferrin functionalization has also
been employed to optimize albumin-based NPs coated with PEG and
containing AZT. A significant increase in rat brain delivery of AZT was
obtained in transferrin-functionalized NPs compared to nude NPs (Mishra et
al. 2006 ). The main role of active targeting to localize NPs into the CNS has
been confirmed by Kuo and Lee ( 2012 ), who have exploited another BBB
target, the bradykinin type II receptor (B2-R), to design a methylmethacrylate-
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=W0VTQU...
17 di 37 03/11/2016 15:43
sulfopropylmethacrylate nanoparticle functionalized with the bradykinin
analogue RMP-7. This nanodevice increased the permeation of D4T, SQV and
delavirdine (DLV) across the BBB, exploiting both a direct target-receptor
interaction and an enhanced paracellular flux through tight junctions between
the brain microvascular endothelial cells (Kuo and Lee 2012 ).
An actively targeted NP has been also developed by Gerson et al. ( 2014 ) to
optimize the brain accumulation of AZT. The encapsulation of this ARV into
cationic nano-gels functionalized with PEG and with a peptide (AP) binding
brain-specific apolipoprotein E receptors (ApoE-R), induced a 10-fold
suppression of HIV-1 activity in the brain of infected mice, significantly lower
activity compared to that with free AZT.
Active targeting of NPs by conjugation of BBB receptors is particularly
promising, since this would provide direct internalization of ARVs into the
BMECs. Furthermore, active targeting is expected to reduce sequestration of
nanodrugs by off-target organs with improved bioavailability in the CNS,
adding a clear benefit to pharmacokinetics of brain-targeted ARVs. The only
concern with active targeting would be that identification of more specific
targets of BBB is needed to exploit proper drug delivery. In this sense, it is
important to highlight that some receptors, such as the TfR-1 of the
bradykinin type II receptors, are overexpressed in various physiological
systems or in pathological conditions such as cancer, while ApoE receptors
are actually brain-specific.
Polymer-based NPs
In 2010, Destache and co-workers demonstrated the ability of poly(dl-lactide-
co-glycolide) (PLGA) nanoparticles to increase the peak concentrations of
RTV, LPV and EFV in the brains of mice injected with the nanoformulated
ARVs in respect to those observed for the mice injected with the free drugs.
Freely injected ARVs did not achieve a concentration of 1 μg/g in brain, while
nanoformulated drugs reached concentrations higher than 5 μg/g in this tissue.
A longer period of detection of LPV, up to 35 days post-injection of the single
dose, was also observed in the brain, upon formulation with PLGA NPs
(Destache et al. 2010 ).
Recently, it has been reported that even ENF, whose low permeation across
the BBB is mainly due to its molecular size and complex structure, can
significantly pass through the barrier upon conjugation with iron oxide NPs
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coated with the amphiphilic PMA polymer (Fiandra et al. 2015). By a
multidisciplinary in vitro and in vivo approach, it has been suggested that the
translocation of nanoformulated ENF across the BBB was possible through
the absorption of the PMA-coated NPs on the apical membrane of the
BMECs, resulting in a passive internalization of the nano-ENF, an
intracellular release of the drug upon degradation of the nanocompex into the
endosomal pathway and, ultimately, an efflux of ENF into brain parenchyma
(Fiandra et al. 2015). The charm of this strategy was that the PMA polymer
was absorbed into microvascular endothelial cells, and then promptly
degraded by the endosomal system to release free ENF, which then could
easily pass through the basolateral side of the cells to reach the CNS. This is a
very relevant point, since various studies have demonstrated that
nanoformulation improves drug delivery through the BBB, but the proper
release kinetics of the free drug after passing the barrier to ensure
antiretroviral activity has been much less investigated.
Conclusions
Suboptimal drug concentration in the brain represents the main limiting step
for HIV eradication from this sanctuary. An adequate drug concentration for
antiretrovirals in the CSF is not given in guidelines, but has generally been
defined as being above the IC50 and IC90. This goal is achieved at lower
levels than those obtained in plasma, since protein binding in the CSF is
negligible (Croteau et al. 2013 ; Di Yacovo et al. 2015 ) and currently the
presence of CSF levels comparable to unbound plasma levels is considered a
marker of efficacy (Letendre et al. 2014 ). However, the main limitation is that
drug concentrations in the CNS tissues are not known and also the degree of
virologic suppression in macrophages cannot be measured.
Different types of nanoparticles have been identified as valid tools to increase
drugs targeting to the brain by exploiting passive or active internalization of
the nanoparticles in the BBB endothelium. More specifically, nano-ARVs
penetration into the CNS was achieved by passive permeation across BBB
(i.e. liposomes and polymeric NPs with amphiphilic properties or coated of
surfactants), also associated to P-glycoprotein efflux escaping (i.e.
RTV-TAT-PLA NPs), or exploiting the active interaction of ligands on NP
surface (Tf, RMP-7, AP) with specific receptors on BMECs luminal
membrane. All these nano-technological approaches resulted somewhere
efficient in favoring ARVs delivery to the CNS. In terms of the ideal
candidate to be nanocomplexed for an efficient CNS penetration, a good
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balance between drug efficiency and neurological safety should be attained.
However, this strategy may be applied to all classes of ARVs, so that patients
infected with drug-resistant strains may benefit from it.
An important aspect of studying penetration of nano-ARVs and their antiviral
effects in the brain deals with the choice of the appropriate animal model.
While mice and rats are generally preferred to evaluate brain targeting and
accumulation (Dusserre et al. 1995 ; Mishra et al. 2006 ; Rao et al. 2008 ;
Destache et al. 2010 ; Fiandra et al. 2015), humanized mice are the most
commonly used animal for HIV research together with non-human primates
(Policicchio et al. 2016). Humanized mice have a great translational power,
since they give the opportunity to investigate human biological processes in
vivo and develop pre-clinical assessment of drugs and human-cell-based
therapeutics before progression to clinic (Denayer et al. 2014). Beyond
human tumor xenografts mainly directed to oncological studies, the most
commonly used humanized mice are those that mimic the human immune
system. Among the numerous applications of these models, the study of
pathogenesis of human-specific infectious agents and its treatment deserve
attention. The development of new drugs towards infectious diseases,
including those aimed to regulate HIV activation and replication, took
advantage from using infected humanized mice (Shultz et al. 2007 ; Singh et
al. 2014 ), and all studies aimed to elucidate the antiretroviral efficiency of
nanoformulated antiretroviral drugs also exploited these experimental models
(Dou et al. 2009 ; Gerson et al. 2014 ; Dash et al. 2012 ; Kanmogne et al.
2012 ).
Finally, we should remember that optimization of delivery of ARVs into the
CNS by nanoformulation, while important for abolishing residual viral
replication in this site with a likely impact on the control of HIV-associated
neurocognitive disorders, is insufficient per se to achieve total eradication of
the virus. Destroying integrated HIV-1 in latently infected cells requires
different strategies and drugs; among others, some strategies need to address
CD4+ T-cellsCD4+ T cells in the lymphoid tissue, but this field still offers
more questions than answers (Kimata et al. 2016 ). Moreover, other biological
barriers are likely to protect other sanctuaries, such as the blood-testis barrier,
although the HPTN 052 study results seem to minimize the risks associated to
this reservoir (Grinsztejn et al. 2014 ). In this setting, studies on the CNS
penetration of nanoformulated compounds should also take into account the
male genital tract compartment, as some authors are doing (Robillard et al.
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2014 ). Lymph node barrier is more a functional barrier made of different
types of cellular sanctuaries that could be faced by conjugating ARVs to
anti-CD4- nanoparticles (Corsi et al. 2016 ).
So, which is the real impact of CNS reservoir on the possibility to eradicate or
‘functionally cure’ the HIV-1 infection? ‘Functional cure’, that is the ability to
suppress HIV replication for years after treatment withdrawal, has been
documented so far for the Mississippi baby (Luzuriaga et al. 2015 ), who
remained viremia-free for 2 years, and for the Visconti cohort (Sáez-Cirión et
al. 2013 ), in which the longest control described is 12 years, always in a
subject infected since birth, without specific strategies targeting the brain,
apart from the choice of antivirals with fair penetration in the CNS. However,
the fact that this has been achieved only in a neonatal setting, when the
blood–brain barrier is still permeable, or at the very beginning of HIV-1
infection (4–10 weeks after infection), when the CNS may not have been
colonized yet or the infection may still be confined to T-lymphocytes
trafficking across the BBB, seems to support rather than to deny the
importance of the CNS reservoir. The only subject who has been cured from
HIV at present, the Berlin patient, was not in acute infection and did not
receive treatment specifically targeted. A double blind, placebo controlled
crossover study is starting to evaluate whether the addition of atorvastatin to a
suppressive antiretroviral regimen has the potential of down-modulating
cerebral monocytes’ activation in subjects with HIV-associated dementia, (
https://clinicaltrials.gov/ct2/show/NCT01600170 ) measuring CNS immune
activation markers and neurocognitive function and defining gene expression
patters of monocyte activation before and following statin treatment.
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However, one further problem is that our diagnostics is currently poor in
helping us monitor these approaches, and biological imaging that may show
where and how much virus hides in tissues when blood tests show optimal
clearance is slowly moving its initial steps (Eck et al. 2010 ; Chen et al.
2014 ). To conclude, we seem to be still distant from the possibility of totally
eradicating HIV, but addressing functional and anatomical reservoirs with a
nanotechnology-based diagnostic and therapeutic approach is mandatory.
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